NanoLockin
NanoLockin is an early-stage startup company developing instruments for the detection and analysis of nanoparticles in all kinds of products. As a spin-off from the Adolphe Merkle Institute - an institution which specializes on nanomaterials research - the team of NanoLockin has long lasting expertise in the analysis of nanomaterials.
NanoLockin is an early-stage startup company developing instruments for the detection and analysis of nanoparticles in all kinds of products. As a spin-off from the Adolphe Merkle Institute - an institution which specializes on nanomaterials research - the team of NanoLockin has long lasting expertise in the analysis of nanomaterials.
Meet our Team
Founded in 2018 by four people, our team currently consists of the following people.
Founded in 2018 by four people, our team currently consists of the following people.
Christoph is responsible for the technical, application and business development. He has a strong technical background in a variety of different fields (Biotechnology, Chemistry, Material Sciences & Biomedical Engineering) and is highly experienced in the field of nanoparticle analytics.
Olivier completed successfully his studies at the HEIA-FR (Haute école d'ingénierie et d'architecture de Fribourg) and obtained his Bachelor's degree in electrical engineering. He has skills in hardware and software development. He is responsible for all the technical aspects.
Gunter supports the CEO in all business-related aspects like business development and the acquisition of financial resources. Gunter has a deep understanding of scientific and business aspects due to 20 years of experience in technology development, both in big companies and startups.
Advisory Board
To help us on our journey, we are very happy to have the following world-class experts in our advisory board.
To help us on our journey, we are very happy to have the following world-class experts in our advisory board.
Prof. Rothen-Rutishauser is a leading scientist in the field of nanoparticle hazard and risk assessment, with a background in cell biology. She is a pioneer in the field of the next generation development of in vitro alternatives to study the interaction of NPs with human tissues. She has a proven track record of successful collaborations with implementation partners, ranging from regulatory bodies, federal agencies to industry partners. The engagement in application-oriented research has been recognized and funded by numerous grants as well as with several prestigious prices.